GSA Capital Partners LLP Has $731,000 Holdings in Rocket Pharmaceuticals, Inc. $RCKT

GSA Capital Partners LLP lifted its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 502.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 224,276 shares of the biotechnology company’s stock after acquiring an additional 187,037 shares during the quarter. GSA Capital Partners LLP’s holdings in Rocket Pharmaceuticals were worth $731,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of RCKT. Vanguard Group Inc. raised its position in Rocket Pharmaceuticals by 12.6% in the third quarter. Vanguard Group Inc. now owns 6,892,204 shares of the biotechnology company’s stock valued at $22,469,000 after purchasing an additional 769,743 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Rocket Pharmaceuticals by 73.6% in the third quarter. JPMorgan Chase & Co. now owns 2,097,033 shares of the biotechnology company’s stock valued at $6,836,000 after buying an additional 889,231 shares during the period. Ballentine Partners LLC bought a new position in Rocket Pharmaceuticals in the 3rd quarter valued at approximately $289,000. Federated Hermes Inc. raised its holdings in Rocket Pharmaceuticals by 0.5% in the 3rd quarter. Federated Hermes Inc. now owns 627,567 shares of the biotechnology company’s stock valued at $2,046,000 after buying an additional 3,264 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in Rocket Pharmaceuticals during the 3rd quarter worth approximately $54,000. Institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT opened at $3.78 on Friday. The company has a current ratio of 7.30, a quick ratio of 7.30 and a debt-to-equity ratio of 0.06. The firm’s fifty day simple moving average is $3.51 and its two-hundred day simple moving average is $3.40. Rocket Pharmaceuticals, Inc. has a 12 month low of $2.19 and a 12 month high of $11.08. The stock has a market capitalization of $409.07 million, a P/E ratio of -1.68 and a beta of 0.48.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on RCKT shares. Bank of America decreased their price target on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. TD Cowen upgraded Rocket Pharmaceuticals to a “hold” rating in a report on Friday, December 19th. JPMorgan Chase & Co. lowered Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Tuesday, November 18th. Wedbush reaffirmed an “outperform” rating and set a $16.00 target price on shares of Rocket Pharmaceuticals in a report on Friday, November 7th. Finally, Morgan Stanley set a $5.00 price target on Rocket Pharmaceuticals in a research note on Thursday, January 8th. Eight research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Rocket Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $14.36.

Insider Activity

In related news, CEO Gaurav Shah sold 12,279 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the sale, the chief executive officer owned 1,052,045 shares of the company’s stock, valued at $3,482,268.95. This trade represents a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Martin Wilson sold 12,253 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $3.31, for a total value of $40,557.43. Following the completion of the sale, the general counsel owned 683,376 shares of the company’s stock, valued at approximately $2,261,974.56. The trade was a 1.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 29,415 shares of company stock worth $97,398. 24.76% of the stock is owned by corporate insiders.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.